BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-744. [PMID: 17580363 DOI: 10.1002/cncr.22852] [Cited by in Crossref: 307] [Cited by in F6Publishing: 289] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Zhu G, Zheng W, Hua J, Yang S, Zhuang J, Wang J, Ye J. Scope definition and resection significance of No. 12a group lymph nodes in gastric cancer. Mol Clin Oncol 2016;5:257-62. [PMID: 27446560 DOI: 10.3892/mco.2016.911] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Manta R, Conigliaro R, Mangiafico S, Forti E, Bertani H, Frazzoni M, Galloro G, Mutignani M, Zullo A. A multimodal, one-session endoscopic approach for management of patients with advanced pancreatic cancer. Surg Endosc 2016;30:1863-8. [PMID: 26194252 DOI: 10.1007/s00464-015-4403-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Ghatnekar O, Andersson R, Svensson M, Persson U, Ringdahl U, Zeilon P, Borrebaeck CA. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer. 2013;133:2392-2397. [PMID: 23649606 DOI: 10.1002/ijc.28256] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
4 Wyse JM, Chen YI, Sahai AV. Celiac plexus neurolysis in the management of unresectable pancreatic cancer: When and how? World J Gastroenterol 2014; 20(9): 2186-2192 [PMID: 24605017 DOI: 10.3748/wjg.v20.i9.2186] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
5 Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P. Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2012;83:909-15. [DOI: 10.1016/j.ijrobp.2011.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 van der Geest LGM, Besselink MGH, Busch ORC, de Hingh IHJT, van Eijck CHJ, Dejong CHC, Lemmens VEPP. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Ann Surg Oncol 2016;23:2002-9. [DOI: 10.1245/s10434-016-5089-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
7 Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, Galloway JR, Adsay NV, Jacobs S, Kooby DA. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:502-513. [PMID: 19885697 DOI: 10.1245/s10434-009-0789-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 5.3] [Reference Citation Analysis]
8 De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol 2018;233:8482-98. [PMID: 29797573 DOI: 10.1002/jcp.26786] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
9 Makris EA, Macbarb R, Harvey DJ, Poultsides GA. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials. Ann Surg Oncol 2017;24:2371-8. [DOI: 10.1245/s10434-017-5826-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010;17:2312-2320. [PMID: 20422460 DOI: 10.1245/s10434-010-1071-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
11 Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, de Jong MC, van den Bergh JE, van Kuijk C, van Delft F, Kazemier G, Meijerink MR. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol. 2017;27:2521-2531. [PMID: 27659702 DOI: 10.1007/s00330-016-4581-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
12 Elberm H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G, Bramhall S, Coldham C, Hammond J. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Eur J Surg Oncol. 2015;41:1500-1507. [PMID: 26346183 DOI: 10.1016/j.ejso.2015.08.158] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
13 Yuan F, Zhou CF, Jin XL. Lumican protein expression in pancreatic ductal adenocarcinoma: clinical significance and correlation with expression of Ki-67, VEGF and mutated P53. Shijie Huaren Xiaohua Zazhi 2012; 20(12): 1018-1024 [DOI: 10.11569/wcjd.v20.i12.1018] [Reference Citation Analysis]
14 Si-Jie H, Wei-Jia X, Yang D, Lie Y, Feng Y, Yong-Jian J, Ji L, Chen J, Liang Z, De-Liang F. How to improve the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis in pain management in patients with pancreatic cancer: analysis in a single center. Surg Laparosc Endosc Percutan Tech. 2014;24:31-35. [PMID: 24487155 DOI: 10.1097/sle.0000000000000032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
15 Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Gutiérrez UC, Sánchez-García Ramos E, Domínguez Rosado I, Chan Núñez LC. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev Gastroenterol Mex (Engl Ed) 2021;86:118-24. [PMID: 32616358 DOI: 10.1016/j.rgmx.2020.04.004] [Reference Citation Analysis]
16 Li XX, Liu NB, Zhu L, Yuan XK, Yang CW, Ren P, Gong LL, Zhao LJ, Xu WG, Wang P. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer. Br J Radiol 2015;88:20140590. [PMID: 25939819 DOI: 10.1259/bjr.20140590] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
17 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810. [PMID: 27160474 DOI: 10.1016/s1470-2045(16)00172-8] [Cited by in Crossref: 416] [Cited by in F6Publishing: 193] [Article Influence: 69.3] [Reference Citation Analysis]
18 Hassid BG, Lucas AL, Salomao M, Weng C, Liu F, Khanna LG, Kumar S, Hwang C, Chabot JA, Frucht H. Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. Pancreas 2014;43:1073-7. [PMID: 24987871 DOI: 10.1097/MPA.0000000000000161] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Miller-ocuin JL, Zenati MS, Ocuin LM, Varley PR, Novak SM, Winters S, Zureikat AH, Zeh HJ, Hogg ME. Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer. Ann Surg Oncol 2017;24:2387-96. [DOI: 10.1245/s10434-017-5880-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
20 Tan X, Lv J, Zhao G, Zhao Z, Li C, Xu Y, Hu M. MicroRNA-4656 is a prognostic factor and tumor suppressor in human pancreatic cancer through a downstream target of TrkA. J Gene Med 2017;19. [PMID: 27936486 DOI: 10.1002/jgm.2938] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011;56:602-609. [PMID: 20614181 DOI: 10.1007/s10620-010-1285-3] [Cited by in Crossref: 102] [Cited by in F6Publishing: 116] [Article Influence: 8.5] [Reference Citation Analysis]
22 Lewis JJ, Kowalski TE. Endoscopic ultrasound and fine needle aspiration in pancreatic cancer. Cancer J. 2012;18:523-529. [PMID: 23187838 DOI: 10.1097/ppo.0b013e318277008e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
23 Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016;34:2899-2905. [PMID: 27325858 DOI: 10.1200/jco.2015.66.3005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
24 Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Mol Cancer Ther 2011;10:2363-72. [PMID: 21971120 DOI: 10.1158/1535-7163.MCT-11-0424] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
25 Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. The Lancet Oncology 2013;14:e476-85. [DOI: 10.1016/s1470-2045(13)70172-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 21.4] [Reference Citation Analysis]
26 Gonoi W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, Tateishi R, Isayama H, Koike K, Ohtomo K. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case–cohort study. Eur Radiol 2017;27:4941-50. [DOI: 10.1007/s00330-017-4895-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
27 Brieau B, Barret M, Rouquette A, Dréanic J, Brezault C, Regnard JF, Coriat R. Resection of Late Pulmonary Metastases from Pancreatic Adenocarcinoma: Is Surgery an Option? Cancer Invest 2015;33:522-5. [PMID: 26461032 DOI: 10.3109/07357907.2015.1080831] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
28 Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010;14:1547-1559. [PMID: 20839073 DOI: 10.1007/s11605-010-1323-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.0] [Reference Citation Analysis]
29 Güngör C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M. Pancreatic cancer. Br J Pharmacol. 2014;171:849-858. [PMID: 24024905 DOI: 10.1111/bph.12401] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
30 Kamarajah SK, Al-Rawashdeh W, Parente A, Atherton P, Salti GI, Dahdaleh FS, Manas D, Hilal MA, White SA. Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study. Eur J Surg Oncol 2021:S0748-7983(21)00949-5. [PMID: 34916085 DOI: 10.1016/j.ejso.2021.12.002] [Reference Citation Analysis]
31 Zhu Y, Zhang JJ, Zhu R, Zhu Y, Liang WB, Gao WT, Yu JB, Xu ZK, Miao Y. The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med Oncol. 2011;28 Suppl 1:S175-S184. [PMID: 20922503 DOI: 10.1007/s12032-010-9683-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
32 Kamarajah SK, Bednar F, Cho CS, Nathan H. Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis. Cancer 2021;127:1266-74. [PMID: 33320344 DOI: 10.1002/cncr.33356] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N, Smith AM. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford) 2015;17:285-91. [PMID: 25431369 DOI: 10.1111/hpb.12355] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
34 Thiruvengadam SS, Chuang J, Huang R, Girotra M, Park WG. Chronic pancreatitis changes in high-risk individuals for pancreatic ductal adenocarcinoma. Gastrointest Endosc. 2019;89:842-851. [PMID: 30145314 DOI: 10.1016/j.gie.2018.08.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
35 Burmeister EA, OʼConnell DL, Beesley VL, Goldstein D, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Wyld D, Neale RE; Pancreatic Cancer Patterns of Care Study Group. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Pancreas 2015;44:1259-65. [PMID: 26262591 DOI: 10.1097/MPA.0000000000000384] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
36 Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31:4229-4234. [PMID: 24145341 DOI: 10.1200/jco.2013.51.7532] [Cited by in Crossref: 78] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
37 Ishikawa M, Yamagami T, Kakizawa H, Hieda M, Toyota N, Fukumoto W, Kajiwara K, Yoshimatsu R, Sudo T, Murakami Y, Awai K. Preoperative Coil Embolization in Patients With a Replaced Hepatic Artery Scheduled for Pancreatectomy With Splanchnic Artery Resection Helps to Prevent Ischemic Organ Injury: . Journal of Computer Assisted Tomography 2016;40:172-6. [DOI: 10.1097/rct.0000000000000325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients with Pancreatic Cancer. J Nucl Med. 2014;55:898-904. [PMID: 24711649 DOI: 10.2967/jnumed.113.131847] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 16.5] [Reference Citation Analysis]
39 Pucci MJ, Kennedy EP, Yeo CJ. Pancreatic cancer. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. Elsevier; 2017. pp. 979-987.e2. [DOI: 10.1016/b978-0-323-34062-5.00062-5] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
41 Kang JS, Higuchi R, He J, Yamamoto M, Wolfgang CL, Cameron JL, Han Y, Son D, Lee S, Choi YJ, Byun Y, Kim H, Kwon W, Kim SW, Park T, Jang JY. Proposal of the minimal number of retrieved regional lymph nodes for accurate staging of distal bile duct cancer and clinical validation of the three-tier lymph node staging system (AJCC 8th edition). J Hepatobiliary Pancreat Sci 2020;27:75-83. [PMID: 31633308 DOI: 10.1002/jhbp.690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Loi M, Magallon-Baro A, Suker M, van Eijck C, Sharma A, Hoogeman M, Nuyttens J. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol 2019;134:67-73. [PMID: 31005226 DOI: 10.1016/j.radonc.2019.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
43 Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, Torkzaban M, Wallace K, Eisenbrey JR, Brody JR, McCormack E, Forsberg F. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther 2021;22:204-15. [PMID: 33691611 DOI: 10.1080/15384047.2021.1881026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kamarajah SK, Sylla P, Markar SR. Racial disparity in curative treatment and survival from solid-organ cancers. Br J Surg 2021:znab089. [PMID: 33824985 DOI: 10.1093/bjs/znab089] [Reference Citation Analysis]
45 Kim CB, Ahmed S, Hsueh EC. Current surgical management of pancreatic cancer. J Gastrointest Oncol 2011;2:126-35. [PMID: 22811842 DOI: 10.3978/j.issn.2078-6891.2011.029] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
46 Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, Vollmer CM. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49-60. [PMID: 23216779 DOI: 10.1111/j.1477-2574.2012.00571.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
47 Gangl O, Fröschl U, Függer R. Surgical quality data and survival after pancreatic cancer resections: a comparison of results for octogenarians and younger patients. Wien Klin Wochenschr 2014;126:757-61. [DOI: 10.1007/s00508-014-0603-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Sartor IT, Zeidán-Chuliá F, Albanus RD, Dalmolin RJ, Moreira JC. Computational analyses reveal a prognostic impact of TULP3 as a transcriptional master regulator in pancreatic ductal adenocarcinoma. Mol Biosyst 2014;10:1461-8. [PMID: 24668219 DOI: 10.1039/c3mb70590k] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
49 Baumgartner JM, Krasinskas A, Daouadi M, Zureikat A, Marsh W, Lee K, Bartlett D, Moser AJ, Zeh HJ. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. J Gastrointest Surg. 2012;16:1152-1159. [PMID: 22399269 DOI: 10.1007/s11605-012-1839-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
50 Liu M, Du Y, Gao J, Liu J, Kong X, Gong Y, Li Z, Wu H, Chen H. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Pancreas. 2013;42:1169-1181. [PMID: 24048456 DOI: 10.1097/mpa.0b013e3182962acb] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
51 Yu Y, Tong Y, Zhong A, Wang Y, Lu R, Guo L. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. Medicine (Baltimore). 2020;99:e23863. [PMID: 33350781 DOI: 10.1097/md.0000000000023863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
52 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget 2016;7:31586-601. [PMID: 26980710 DOI: 10.18632/oncotarget.8040] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
53 Zhao H, Wang Q, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J. Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer. Pancreas 2016;45:204-10. [PMID: 26418905 DOI: 10.1097/MPA.0000000000000453] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
54 Vicente E, Quijano Y, Ielpo B, Duran H, Diaz E, Fabra I, Malave L, Caruso R. Role of robotic-assisted pancreatic surgery: lessons learned from our initial experience. Hepatobiliary Pancreat Dis Int 2017;16:652-8. [PMID: 29291786 DOI: 10.1016/S1499-3872(17)60054-7] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B. DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair (Amst) 2021;103:103116. [PMID: 33882393 DOI: 10.1016/j.dnarep.2021.103116] [Reference Citation Analysis]
56 Lucena GCM, Barros RA. PRE-OPERATIVE BILIARY DRAINAGE IN THE PERIAMPULLARY NEOPLASIA - A SYSTEMATIC REVIEW. Arq Bras Cir Dig 2018;31:e1372. [PMID: 29972400 DOI: 10.1590/0102-672020180001e1372] [Reference Citation Analysis]
57 Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? World J Gastrointest Oncol 2015; 7(12): 375-382 [PMID: 26689800 DOI: 10.4251/wjgo.v7.i12.375] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
58 Hashim T, Sanam K, Revilla-Martinez M, Morgan CJ, Tallaj JA, Pamboukian SV, Loyaga-Rendon RY, George JF, Acharya D. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8:880-886. [PMID: 26179184 DOI: 10.1161/circheartfailure.114.001778] [Cited by in Crossref: 69] [Cited by in F6Publishing: 18] [Article Influence: 9.9] [Reference Citation Analysis]
59 Krantz SB, Shields MA, Dangi-Garimella S, Bentrem DJ, Munshi HG. Contribution of epithelial-mesenchymal transition to pancreatic cancer progression. Cancers (Basel). 2010;2:2084-2097. [PMID: 24281219 DOI: 10.3390/cancers2042084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
60 Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979-985. [PMID: 25734581 DOI: 10.3109/0284186x.2015.1004367] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
61 Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, Grem J, Sasson AR, Singh PK. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Res. 2017;77:5503-5517. [PMID: 28811332 DOI: 10.1158/0008-5472.can-16-3062] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
62 Franklin O, Billing O, Öhlund D, Berglund A, Herdenberg C, Wang W, Hellman U, Sund M. Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer. J Pathol Clin Res 2019;5:130-41. [PMID: 30456933 DOI: 10.1002/cjp2.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21:1530-1537. [PMID: 24473642 DOI: 10.1245/s10434-014-3486-z] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 11.5] [Reference Citation Analysis]
64 Abbott DE, Baker MS, Talamonti MS. Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010;101:315-320. [PMID: 20187063 DOI: 10.1002/jso.21469] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
65 Park JB, Kim YH, Kim J, Chang HM, Kim TW, Kim SC, Kim PN, Han DJ. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. J Vasc Interv Radiol. 2012;23:635-641. [PMID: 22525021 DOI: 10.1016/j.jvir.2012.01.080] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
66 Juhl K, Christensen A, Rubek N, Karnov KKS, von Buchwald C, Kjaer A. Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery. Oncotarget 2019;10:6308-16. [PMID: 31695839 DOI: 10.18632/oncotarget.27220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
67 Hou YC, Chao YJ, Tung HL, Wang HC, Shan YS. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer. 2014;120:2766-2777. [PMID: 24839953 DOI: 10.1002/cncr.28774] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
68 Parbhu SK, Adler DG. Pancreatic neuroendocrine tumors: contemporary diagnosis and management. Hosp Pract (1995) 2016;44:109-19. [PMID: 27404266 DOI: 10.1080/21548331.2016.1210474] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
69 Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol Ther. 2017;179:158-170. [PMID: 28549596 DOI: 10.1016/j.pharmthera.2017.05.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 12.6] [Reference Citation Analysis]
70 Wang Q, Ni Q, Wang X, Zhu H, Wang Z, Huang J. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med Oncol 2015;32:372. [PMID: 25428385 DOI: 10.1007/s12032-014-0372-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
71 Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. Ann Surg 2013;257:1096-102. [PMID: 23360921 DOI: 10.1097/SLA.0b013e318275b7e5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
72 Okui M, Yamamichi T, Asakawa A, Harada M, Horio H. Resection for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc Surg 2017;50:326-8. [PMID: 29124023 DOI: 10.5090/kjtcs.2017.50.5.326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Yuan C, Morales-Oyarvide V, Babic A, Clish CB, Kraft P, Bao Y, Qian ZR, Rubinson DA, Ng K, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017;35:1822-1828. [PMID: 28358654 DOI: 10.1200/jco.2016.71.2026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 9.2] [Reference Citation Analysis]
74 Hamada T, Yuan C, Bao Y, Zhang M, Khalaf N, Babic A, Morales-Oyarvide V, Cochrane BB, Gaziano JM, Giovannucci EL, Kraft P, Manson JE, Ng K, Nowak JA, Rohan TE, Sesso HD, Stampfer MJ, Amundadottir LT, Fuchs CS, De Vivo I, Ogino S, Wolpin BM. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev 2019;28:1868-75. [PMID: 31427306 DOI: 10.1158/1055-9965.EPI-19-0577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
75 Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012;118:3026-3035. [PMID: 22020923 DOI: 10.1002/cncr.26633] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
76 Faluyi OO, Connor JL, Chatterjee M, Ikin C, Wong H, Palmer DH. Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. Br J Cancer 2017;116:424-31. [PMID: 28081546 DOI: 10.1038/bjc.2016.406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
77 Pu N, Yin L, Habib JR, Gao S, Hu H, Zhu Y, Wu Y, Yu J, Lou W. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Future Oncology 2019;15:3457-65. [DOI: 10.2217/fon-2019-0264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.BMC Cancer. 2017;17:576. [PMID: 28851316 DOI: 10.1186/s12885-017-3604-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
79 Li YJ, Huang GL, Sun XL, Zhao XC, Li ZG. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J Surg Oncol 2016;14:60. [PMID: 26927794 DOI: 10.1186/s12957-016-0809-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
80 Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, Qian ZR, Ng K, Rubinson DA, Kraft P, Giovannucci EL, Stampfer MJ, Fuchs CS, Ogino S, Wolpin BM. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018;16:1300-1306.e3. [PMID: 29474971 DOI: 10.1016/j.cgh.2018.02.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
81 Yalçın S, Erkan M, Ünsoy G, Parsian M, Kleeff J, Gündüz U. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomedicine & Pharmacotherapy 2014;68:737-43. [DOI: 10.1016/j.biopha.2014.07.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
82 Dohopolski MJ, Glaser SM, Vargo JA, Balasubramani GK, Beriwal S. Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival. J Gastrointest Oncol 2017;8:766-77. [PMID: 29184680 DOI: 10.21037/jgo.2017.08.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
83 Williams JL, Nguyen AH, Rochefort M, Muthusamy VR, Wainberg ZA, Dawson DW, Tomlinson JS, Hines OJ, Reber HA, Donahue TR. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. J Surg Oncol 2015;112:396-402. [PMID: 26303811 DOI: 10.1002/jso.24011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
84 Liu L, Xu HX, He M, Wang W, Wang WQ, Wu CT, Wei RQ, Liang Y, Gao HL, Liu C, Xu J, Long J, Ni QX, Shao CH, Wang J, Yu XJ. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. Surgery 2018;163:1280-94. [PMID: 29548773 DOI: 10.1016/j.surg.2018.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
85 Meleady P, Abdul Rahman R, Henry M, Moriarty M, Clynes M. Proteomic analysis of pancreatic ductal adenocarcinoma. Expert Rev Proteomics 2020;17:453-67. [PMID: 32755290 DOI: 10.1080/14789450.2020.1803743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, Ballard S, Lancaster J, Hamilton W, Rubin GP, Emery JD. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol 2016;1:298-306. [PMID: 28404200 DOI: 10.1016/S2468-1253(16)30079-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
87 Lin R, Han CQ, Wang WJ, Liu J, Qian W, Ding Z, Hou XH. Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma. J Huazhong Univ Sci Technolog Med Sci 2017;37:612-20. [PMID: 28786050 DOI: 10.1007/s11596-017-1780-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
88 Ahn SJ, Choi SJ, Kim HS. Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography. J Gastrointest Cancer 2017;48:164-9. [PMID: 27699624 DOI: 10.1007/s12029-016-9876-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
89 Kamarajah SK, Markar SR, Phillips AW, Salti GI, Dahdaleh F, Griffiths EA. Palliative gastrectomy for metastatic gastric adenocarcinoma: A national population-based cohort study. Surgery 2021:S0039-6060(21)00699-1. [PMID: 34389165 DOI: 10.1016/j.surg.2021.07.016] [Reference Citation Analysis]
90 Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ, Moser AJ. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12:1664-1672; discussion 1672-1673. [PMID: 18677542 DOI: 10.1007/s11605-008-0577-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
91 Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 2016;22:2565-74. [PMID: 26719427 DOI: 10.1158/1078-0432.CCR-15-1732] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
92 Olivares O, Vasseur S. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze. Int J Cancer 2016;138:787-96. [PMID: 25732227 DOI: 10.1002/ijc.29501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
93 Koopmann BD, Harinck F, Kroep S, Konings IC, Naber SK, Lansdorp-Vogelaar I, Fockens P, van Hooft JE, Cahen DL, van Ballegooijen M, Bruno MJ, de Kok IM. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Int J Cancer. 2021;. [PMID: 33644856 DOI: 10.1002/ijc.33540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016;7:547-555. [PMID: 27563444 DOI: 10.21037/jgo.2016.03.15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
95 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
96 Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17:94-100; discussion p. 100-101. [PMID: 23229886 DOI: 10.1007/s11605-012-2064-6] [Cited by in Crossref: 115] [Cited by in F6Publishing: 106] [Article Influence: 11.5] [Reference Citation Analysis]
97 Truty MJ. Commentary: Two papers, 2 tumor types, same conclusion. Surgery 2020;168:1019-20. [PMID: 32896374 DOI: 10.1016/j.surg.2020.07.034] [Reference Citation Analysis]
98 de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8-16. [PMID: 25084222 DOI: 10.1016/j.ejphar.2014.07.041] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 32.3] [Reference Citation Analysis]
99 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
100 American Joint Committee on Cancer. Exocrine and Endocrine Pancreas. AJCC Cancer Staging Manual. New York: Springer; 2010. pp. 241-9. [DOI: 10.1007/978-0-387-88441-7_24] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
101 Catalano M, Conca R, Petrioli R, Ramello M, Roviello G. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancer Manag Res. 2020;12:10271-10278. [PMID: 33116881 DOI: 10.2147/cmar.s267393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Zhou L, Baba Y, Kitano Y, Miyake K, Zhang X, Yamamura K, Kosumi K, Kaida T, Arima K, Taki K, Higashi T, Imai K, Hashimoto D, Yamashita Y, Chikamoto A, Beppu T, Tan X, Baba H. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. Med Oncol 2016;33. [DOI: 10.1007/s12032-016-0745-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zihao G, Jie Z, Yan L, Jing Z, Jing C, Xue L, Jing Z, Heng LW, Ru G, Jianyu H. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer. J Clin Gastroenterol. 2013;47:69-75. [PMID: 22914344 DOI: 10.1097/mcg.0b013e3182601752] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
104 Wang C, Sun Y, Wu H, Yu S, Zhang L, Meng Y, Liu M, Yang H, Liu P, Mao X, Lu Z, Chen J. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 2015;36:9447-56. [PMID: 26124009 DOI: 10.1007/s13277-015-3690-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
105 Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Ann Surg Oncol 2017;24:3674-82. [PMID: 28871564 DOI: 10.1245/s10434-017-6076-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
106 Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol. 2013;107:97-103. [PMID: 22991309 DOI: 10.1002/jso.23267] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
107 Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB, Taieb J. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 2011;35:364-74. [PMID: 21435966 DOI: 10.1016/j.clinre.2011.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
108 Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 2017;24:2023-2030. [PMID: 28213792 DOI: 10.1245/s10434-017-5810-x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 25.2] [Reference Citation Analysis]
109 Lu Z, Dong TH, Si PR, Shen W, Bi YL, Min M, Chen X, Liu Y. Continuous Low-dose-rate Irradiation of Iodine-125 Seeds Inhibiting Perineural Invasion in Pancreatic Cancer. Chin Med J (Engl) 2016;129:2460-8. [PMID: 27748339 DOI: 10.4103/0366-6999.191777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
110 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
111 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
112 Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011;29:3541-3546. [PMID: 21844506 DOI: 10.1200/jco.2010.32.2750] [Cited by in Crossref: 150] [Cited by in F6Publishing: 54] [Article Influence: 13.6] [Reference Citation Analysis]
113 Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 2017;113:268-82. [DOI: 10.1016/j.critrevonc.2017.03.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
114 Khokhlova TD, Hwang JH. HIFU for Palliative Treatment of Pancreatic Cancer. Adv Exp Med Biol 2016;880:83-95. [PMID: 26486333 DOI: 10.1007/978-3-319-22536-4_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
115 Bhatti I, Ojo D, Dennison AR, Rees Y, Elabassy M, Garcea G. Percutaneous Pancreatic Biopsies-Still an Effective Method for Histologic Confirmation of Malignancy. Surg Laparosc Endosc Percutan Tech 2016;26:334-7. [PMID: 27438169 DOI: 10.1097/SLE.0000000000000288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
116 Lee EW, Shahrouki P, Peterson S, Tafti BA, Ding PX, Kee ST. Safety of Irreversible Electroporation Ablation of the Pancreas. Pancreas 2021;50:1281-6. [PMID: 34860812 DOI: 10.1097/MPA.0000000000001916] [Reference Citation Analysis]
117 Verbeke CS, Smith AM. Survival After Pancreaticoduodenectomy Is Not Improved by Extending Resections to Achieve Negative Margins. Annals of Surgery 2010;251:776-7. [DOI: 10.1097/sla.0b013e3181d57af6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
118 Yoon DM, Yoon KB, Baek IC, Ko SH, Kim SH. Predictors of analgesic efficacy of neurolytic celiac plexus block in patients with unresectable pancreatic cancer: the importance of timing. Support Care Cancer 2018;26:2023-30. [DOI: 10.1007/s00520-018-4043-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
119 Tsoukalas N, Triantafyllidis A, Tolia M, Galanopoulos M, Kostakis ID, Demiri S, Toumpanakis C, Koumakis G. Occipital Headache as Initial Manifestation of a Pancreatic Neuroendocrine Tumor. J Gastrointest Cancer 2018;49:501-3. [PMID: 28283989 DOI: 10.1007/s12029-017-9931-z] [Reference Citation Analysis]
120 Zhang JJ, Zhu Y, Xie KL, Peng YP, Tao JQ, Tang J, Li Z, Xu ZK, Dai CC, Qian ZY, Jiang KR, Wu JL, Gao WT, Du Q, Miao Y. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Mol Cancer 2014;13:130. [PMID: 24884523 DOI: 10.1186/1476-4598-13-130] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
121 Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol. 2013;5:81-89. [PMID: 23323149 DOI: 10.1177/1758834012462463] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
122 Wu J, Song L, Zhang Y, Zhao DY, Guo B, Liu J. Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer. Tumour Biol 2014;35:2753-7. [PMID: 24264311 DOI: 10.1007/s13277-013-1363-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
123 Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, Mochizuki A, Goodenowe DB. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 2015; 21(21): 6604-6612 [PMID: 26074698 DOI: 10.3748/wjg.v21.i21.6604] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
124 Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15:1611-1617. [PMID: 21725701 DOI: 10.1007/s11605-011-1605-8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
125 Nassar AP Jr, Dettino ALA, Amendola CP, Dos Santos RA, Forte DN, Caruso P. Oncologists' and Intensivists' Attitudes Toward the Care of Critically Ill Patients with Cancer. J Intensive Care Med 2019;34:811-7. [PMID: 28675982 DOI: 10.1177/0885066617716105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Cucchetti A, Ercolani G, Pezzilli R, Cescon M, Frascaroli G, Pinna AD. The Health Gain Obtainable from Pancreatic Resection for Adenocarcinoma in the Elderly. World J Surg 2017;41:1063-72. [PMID: 27826771 DOI: 10.1007/s00268-016-3793-6] [Reference Citation Analysis]
127 Cucchetti A, Ercolani G, Cescon M, Brandi G, Taffurelli G, Maroni L, Ravaioli M, Pezzilli R, Pinna AD. Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. Pancreas 2016;45:714-9. [DOI: 10.1097/mpa.0000000000000523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
128 Azap RA, Diaz A, Hyer JM, Tsilimigras DI, Mirdad RS, Ejaz A, Pawlik TM. Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. Ann Surg Oncol 2021. [PMID: 33844130 DOI: 10.1245/s10434-021-09911-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 Navarro S, Vaquero E, Maurel J, Bombí JA, De Juan C, Feliu J, Fernández Cruz L, Ginés À, Girela E, Rodríguez R, Sabater L. Recomendaciones para el diagnóstico, la estadificación y el tratamiento del cáncer de páncreas (parte I). Medicina Clínica 2010;134:643-55. [DOI: 10.1016/j.medcli.2009.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
130 Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. J Gastrointest Cancer 2018;49:481-6. [PMID: 28924968 DOI: 10.1007/s12029-017-0007-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
131 Xia X, Wu W, Huang C, Cen G, Jiang T, Cao J, Huang K, Qiu Z. SMAD4 and its role in pancreatic cancer. Tumour Biol. 2015;36:111-119. [PMID: 25464861 DOI: 10.1007/s13277-014-2883-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
132 Ady JW, Heffner J, Klein E, Fong Y. Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virotherapy. 2014;3:35-46. [PMID: 27512661 DOI: 10.2147/ov.s53858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
133 Kamarajah SK, Nathan H. Strengths and Limitations of Registries in Surgical Oncology Research. J Gastrointest Surg 2021. [PMID: 34506025 DOI: 10.1007/s11605-021-05094-y] [Reference Citation Analysis]
134 Jeon CY, Li D, Cleary S, Stolzenberg-Solomon R, Bosetti C, La Vecchia C, Porta M, Toriola AT, Hung RJ, Kurtz RC, Olson SH. The Association of Recently Diagnosed Diabetes and Long-term Diabetes With Survival in Pancreatic Cancer Patients: A Pooled Analysis. Pancreas. 2018;47:314-320. [PMID: 29401167 DOI: 10.1097/mpa.0000000000000989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Dobosz Ł, Stefaniak T, Dobrzycka M, Wieczorek J, Franczak P, Ptaszyńska D, Zasada K, Kanyion P. Invasive treatment of pain associated with pancreatic cancer on different levels of WHO analgesic ladder. BMC Surg 2016;16:20. [PMID: 27090728 DOI: 10.1186/s12893-016-0136-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
136 Zhang A, Ren S, Yuan Y, Li X, Zhu X, Jiang L, Li D, Zuo C. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine (Baltimore) 2019;98:e15064. [PMID: 30921238 DOI: 10.1097/MD.0000000000015064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
137 Klompmaker S, Besselink MG. ASO Author Reflections: Distal Pancreatectomy with Celiac Axis Resection for Locally Advanced Pancreatic Cancer-Patient Selection and Surgical Experience are Key. Ann Surg Oncol 2018;25:828-9. [PMID: 30456669 DOI: 10.1245/s10434-018-7033-1] [Reference Citation Analysis]
138 El-bared N, Portelance L, Spieler BO, Kwon D, Padgett KR, Brown KM, Mellon EA. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. Practical Radiation Oncology 2019;9:e46-54. [DOI: 10.1016/j.prro.2018.08.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
139 McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:19-27. [PMID: 25726049 DOI: 10.1053/j.seminoncol.2014.12.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
140 Burchard PR, Chacon AC, Melucci A, Casabianca AS, Goyal S, Switchenko JM, Maithel SK, Kooby DA, Carpizo DR, Shah MM. Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma. J Surg Oncol 2022. [PMID: 34994405 DOI: 10.1002/jso.26785] [Reference Citation Analysis]
141 Kamarajah SK, White SA, Naffouje SA, Salti GI, Dahdaleh F. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. Ann Surg Oncol 2021. [PMID: 33786676 DOI: 10.1245/s10434-021-09823-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Fortea-sanchis C, Gómez-quiles L, Martínez-ramos D, Escrig Sos J, Paiva-coronel GA, Queralt-martín R, Villarín-rodríguez Á, Granel-villach L, Salvador-sanchis JL. Rentabilidad diagnóstica de la punción percutánea pancreática en función del tamaño de la lesión. Cirugía Española 2013;91:361-5. [DOI: 10.1016/j.ciresp.2012.10.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, Ganguly E, Vecchio J. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc. 2011;74:87-95. [PMID: 21704809 DOI: 10.1016/j.gie.2011.03.1235] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
144 Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, Nathan H. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. Annals of Surgery 2021;273:587-94. [DOI: 10.1097/sla.0000000000003242] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
145 Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery 2017;162:104-11. [PMID: 28238344 DOI: 10.1016/j.surg.2016.12.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
146 Lee KH, Chie EK, Im SA, Kim JH, Kwon J, Han SW, Oh DY, Jang JY, Kim JS, Kim TY, Bang YJ, Kim SW, Ha SW. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Res Treat 2020. [PMID: 33421976 DOI: 10.4143/crt.2020.928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Shah MM, NeMoyer RE, Greco SH, Chen C, Moore DF, Grandhi MS, Langan RC, Kennedy TJ, Javidian P, Jabbour SK, Alexander HR, August DA, Carpizo DR. Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database. J Pancreat Cancer 2020;6:64-72. [PMID: 32766509 DOI: 10.1089/pancan.2019.0017] [Reference Citation Analysis]
148 Park J, Choi Y, Namkung J, Yi SG, Kim H, Yu J, Kim Y, Kwon MS, Kwon W, Oh DY, Kim SW, Jeong SY, Han W, Lee KE, Heo JS, Park JO, Park JK, Kim SC, Kang CM, Lee WJ, Lee S, Han S, Park T, Jang JY, Kim Y. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget 2017;8:93117-30. [PMID: 29190982 DOI: 10.18632/oncotarget.21861] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
149 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers (Basel) 2019;11:E93. [PMID: 30650521 DOI: 10.3390/cancers11010093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
151 Kamarajah SK, Bednar F, Cho CS, Nathan H. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. J Gastrointest Surg 2021;25:1805-14. [PMID: 33230687 DOI: 10.1007/s11605-020-04879-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Ozkan E, Balachandran A, Bhosale PR, Tamm EP, Marcal LP, Szklaruk J. Pictorial essay: multimodality imaging of metastases from pancreatic ductal adenocarcinoma. Clinical Imaging 2010;34:277-87. [DOI: 10.1016/j.clinimag.2009.06.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
153 Teriaca MA, Loi M, Suker M, Eskens FALM, van Eijck CHJ, Nuyttens JJ. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother Oncol 2021;155:232-6. [PMID: 33217500 DOI: 10.1016/j.radonc.2020.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Suker M, Groot Koerkamp B, Nuyttens JJ, Dwarkasing RS, Homs MYV, Eskens FALM, van Eijck CHJ. The yield of chest computed tomography in patients with locally advanced pancreatic cancer. J Surg Oncol 2020;122:450-6. [PMID: 32378193 DOI: 10.1002/jso.25968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
155 Kim M, Kang TW, Cha DI, Kim YK, Kim SH, Jang KT, Han IW, Sohn I. Prediction and clinical implications of portal vein/superior mesenteric vein invasion in patients with resected pancreatic head cancer: the significance of preoperative CT parameters. Clin Radiol 2018;73:564-73. [PMID: 29519500 DOI: 10.1016/j.crad.2018.01.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
156 Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6:1301-1308. [PMID: 18948228 DOI: 10.1016/j.cgh.2008.09.014] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 7.0] [Reference Citation Analysis]
157 Pointer DT Jr, Al-Qurayshi Z, Hamner JB, Slakey DP, Kandil E. Factors leading to pancreatic resection in patients with pancreatic cancer: a national perspective. Gland Surg 2018;7:207-15. [PMID: 29770314 DOI: 10.21037/gs.2017.12.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2012;16:29-37. [PMID: 22050964 DOI: 10.1016/j.anndiagpath.2011.08.005] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 7.1] [Reference Citation Analysis]
159 Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Seminars in Immunology 2014;26:80-7. [DOI: 10.1016/j.smim.2014.01.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
160 Mosquera C, Maglic D, Zervos EE. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Cancer Genet 2016;209:567-81. [PMID: 27613577 DOI: 10.1016/j.cancergen.2016.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
161 Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer: Initiation of Adjuvant Chemotherapy. Cancer 2016;122:2979-87. [DOI: 10.1002/cncr.30163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
162 Wei W, Liu Y, Lu Y, Yang B, Tang L. LncRNA XIST Promotes Pancreatic CancerProliferation Through miR-133a/EGFR. J Cell Biochem. 2017;118:3349-3358. [PMID: 28295543 DOI: 10.1002/jcb.25988] [Cited by in Crossref: 114] [Cited by in F6Publishing: 123] [Article Influence: 22.8] [Reference Citation Analysis]
163 Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9. [PMID: 28701476 DOI: 10.1126/scitranslmed.aah5583] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 25.3] [Reference Citation Analysis]
164 Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 2019;19:40. [PMID: 30621618 DOI: 10.1186/s12885-018-5244-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
165 Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 2018;9:358-68. [PMID: 29316343 DOI: 10.1002/jcsm.12251] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
166 Chen MJ, Tsan YT, Liou JM, Lee YC, Wu MS, Chiu HM, Wang HP, Chen PC. Statins and the risk of pancreatic cancer in Type 2 diabetic patients--A population-based cohort study. Int J Cancer. 2016;138:594-603. [PMID: 26296262 DOI: 10.1002/ijc.29813] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
167 Arpalahti L, Saukkonen K, Hagström J, Mustonen H, Seppänen H, Haglund C, Holmberg CI. Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Tumour Biol 2017;39:1010428317710411. [PMID: 28653876 DOI: 10.1177/1010428317710411] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
168 Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers (Basel). 2018;10. [PMID: 29320420 DOI: 10.3390/cancers10010016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
169 Suker M, Nuyttens JJ, Eskens FALM, Haberkorn BCM, Coene PLO, van der Harst E, Bonsing BA, Vahrmeijer AL, Mieog JSD, Jan Swijnenburg R, Roos D, Koerkamp BG, van Eijck CHJ. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine 2019;17:100200. [PMID: 31891135 DOI: 10.1016/j.eclinm.2019.10.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
170 Shangguan A, Shang N, Figini M, Pan L, Yang J, Ma Q, Hu S, Eresen A, Sun C, Wang B, Velichko Y, Yaghmai V, Zhang Z. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Cytotherapy 2020;22:6-15. [DOI: 10.1016/j.jcyt.2019.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
171 Zhu Y, Zhang JJ, Xie KL, Tang J, Liang WB, Zhu R, Zhu Y, Wang B, Tao JQ, Zhi XF. Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling. J Transl Med. 2014;12:309. [PMID: 25367394 DOI: 10.1186/s12967-014-0309-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
172 Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg. 2009;13:26-34. [PMID: 18946644 DOI: 10.1007/s11605-008-0648-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
173 Wörmann SM, Algül H. Risk Factors and Therapeutic Targets in Pancreatic Cancer. Front Oncol 2013;3. [DOI: 10.3389/fonc.2013.00282] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
174 Usón Junior PL, França MS, Rodrigues HV, Macedo AL, Goldenberg A, Smaletz O, Armentano DP, Simon SD, Gansl RC. Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo) 2015;13:347-51. [PMID: 26313433 DOI: 10.1590/S1679-45082015AO3303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Raval MV, Bilimoria KY, Talamonti MS. Quality improvement for pancreatic cancer care: is regionalization a feasible and effective mechanism? Surg Oncol Clin N Am. 2010;19:371-390. [PMID: 20159520 DOI: 10.1016/j.soc.2009.11.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
176 Bruno MJ. Early diagnosis of pancreatic cancer; looking for a needle in a haystack? Gut 2013;62:955-6. [PMID: 22990305 DOI: 10.1136/gutjnl-2012-303168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
177 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
178 Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG 3rd, Roman SA, Sosa JA. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol 2017;116:127-32. [PMID: 28407261 DOI: 10.1002/jso.24630] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
179 Kamarajah SK, Markar SR, Phillips AW, Salti GI, Dahdaleh FS. Local Endoscopic Resection is Inferior to Gastrectomy for Early Clinical Stage T1a and T1b Gastric Adenocarcinoma: A Propensity-Matched Study. Ann Surg Oncol 2021;28:2992-8. [PMID: 33452601 DOI: 10.1245/s10434-020-09485-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 He XK, Ding Y, Sun LM. Contrast-enhanced endoscopic ultrasound for differential diagnosis of pancreatic cancer: an updated meta-analysis. Oncotarget 2017;8:66392-401. [PMID: 29029521 DOI: 10.18632/oncotarget.18915] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
181 Franklin O, Jonsson P, Billing O, Lundberg E, Öhlund D, Nyström H, Lundin C, Antti H, Sund M. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Ann Surg 2018;267:775-81. [PMID: 28425921 DOI: 10.1097/SLA.0000000000002124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
182 Unger K, Mehta KY, Kaur P, Wang Y, Menon SS, Jain SK, Moonjelly RA, Suman S, Datta K, Singh R, Fogel P, Cheema AK. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018;9:23078-23090. [PMID: 29796173 DOI: 10.18632/oncotarget.25212] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
183 Yu HF, Zhao BQ, Li YC, Fu J, Jiang W, Xu RW, Yang HC, Zhang XJ. Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8th Edition) staging system for pancreatic cancer. World J Gastroenterol 2018; 24(22): 2400-2405 [PMID: 29904247 DOI: 10.3748/wjg.v24.i22.2400] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Catalano M, Roviello G, Conca R, D'Angelo A, Palmieri VE, Panella B, Petrioli R, Ianza A, Nobili S, Mini E, Ramello M. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Curr Cancer Drug Targets 2020;20:887-95. [PMID: 32957885 DOI: 10.2174/1568009620999200918122426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
185 El Hajj II, Al-haddad M. Endoscopic ultrasound-guided tissue acquisition of pancreatic masses. Techniques in Gastrointestinal Endoscopy 2018;20:30-8. [DOI: 10.1016/j.tgie.2018.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
186 Winner M, Wilson A, Yahanda A, Gani F, Pawlik TM. Cancer surgeons' attitudes and practices about discussing the chance of operative “cure”. Surgery 2016;160:1619-27. [DOI: 10.1016/j.surg.2016.06.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
187 Ebrahimi G, Rasch CRN, van Tienhoven G. Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience. Acta Oncol. 2018;57:697-700. [PMID: 29157074 DOI: 10.1080/0284186x.2017.1400692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
188 Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18:619-627. [PMID: 21213060 DOI: 10.1245/s10434-010-1456-7] [Cited by in Crossref: 146] [Cited by in F6Publishing: 120] [Article Influence: 13.3] [Reference Citation Analysis]
189 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
190 Chen JW, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, Toouli J, Padbury RT. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford). 2010;12:101-108. [PMID: 20495653 DOI: 10.1111/j.1477-2574.2009.00140.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
191 Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Kallio P, Alitalo K, Seppänen H, Haglund C. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma. BMC Cancer 2016;16:472. [PMID: 27411302 DOI: 10.1186/s12885-016-2497-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
192 Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer & lt; 1 or 2 cm. Ann Surg Oncol. 2013;20:357-361. [PMID: 22941171 DOI: 10.1245/s10434-012-2621-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
193 Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683-90. [PMID: 18183467 DOI: 10.1245/s10434-007-9747-3] [Cited by in Crossref: 1127] [Cited by in F6Publishing: 1140] [Article Influence: 80.5] [Reference Citation Analysis]
194 Martin RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012;215:361-369. [PMID: 22726894 DOI: 10.1016/j.jamcollsurg.2012.05.021] [Cited by in Crossref: 169] [Cited by in F6Publishing: 149] [Article Influence: 16.9] [Reference Citation Analysis]
195 Wang BJ, Wang L, Yang SY, Liu ZJ. Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions. Clin Transl Oncol 2015;17:215-22. [PMID: 25183049 DOI: 10.1007/s12094-014-1216-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
196 Bliss LA, Witkowski ER, Yang CJ, Tseng JF. Outcomes in operative management of pancreatic cancer. J Surg Oncol 2014;110:592-8. [PMID: 25111970 DOI: 10.1002/jso.23744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
197 Suker M, Koerkamp BG, Coene PP, van der Harst E, Bonsing BA, Vahrmeijer AL, Mieog JSD, Swijnenburg RJ, Dwarkasing RS, Roos D, van Eijck CHJ. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. Eur J Surg Oncol 2019;45:1906-11. [PMID: 31186205 DOI: 10.1016/j.ejso.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
198 Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008;207:510-519. [PMID: 18926452 DOI: 10.1016/j.jamcollsurg.2008.04.033] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 8.1] [Reference Citation Analysis]
199 McDowell CT, Klamer Z, Hall J, West CA, Wisniewski L, Powers TW, Angel PM, Mehta AS, Lewin DN, Haab BB, Drake RR. Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues. Mol Cell Proteomics 2020;20:100012. [PMID: 33581409 DOI: 10.1074/mcp.RA120.002256] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
200 Kotteas E, Saif MW, Syrigos K. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol 2016;142:1795-805. [PMID: 26843405 DOI: 10.1007/s00432-016-2119-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
201 Cramer JD, Reddy A, Ferris RL, Duvvuri U, Samant S. Comparison of the seventh and eighth edition american joint committee on cancer oral cavity staging systems. Laryngoscope 2018;128:2351-60. [PMID: 29658104 DOI: 10.1002/lary.27205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
202 Kwak BJ, Kim SC, Song KB, Lee JH, Hwang DW, Park KM, Lee YJ. Prognostic factors associated with early mortality after surgical resection for pancreatic adenocarcinoma. Korean J Hepatobiliary Pancreat Surg 2014;18:138-46. [PMID: 26155266 DOI: 10.14701/kjhbps.2014.18.4.138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
203 Gonoi W, Okuma H, Hayashi TY, Akahane M, Nakai Y, Tateishi R, Mizuno S, Suzuki Y, Mitsuda M, Matsuda K, Nakagawa K, Isayama H, Miyagawa K, Koike K, Abe O. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Saudi J Gastroenterol 2019;25:390-6. [PMID: 31274472 DOI: 10.4103/sjg.SJG_56_19] [Reference Citation Analysis]
204 Hsieh MC, Chang WW, Yu HH, Lu CY, Chang CL, Chow JM, Chen SU, Cheng Y, Wu SY. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018;7:2328-2338. [PMID: 29665327 DOI: 10.1002/cam4.1479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
205 Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients. Annals of Surgery 2008;247:490-500. [DOI: 10.1097/sla.0b013e31815b9cae] [Cited by in Crossref: 236] [Cited by in F6Publishing: 98] [Article Influence: 16.9] [Reference Citation Analysis]
206 Lemke J, Scheele J, Kapapa T, Wirtz CR, Henne-Bruns D, Kornmann M. Brain metastasis in pancreatic cancer. Int J Mol Sci. 2013;14:4163-4173. [PMID: 23429199 DOI: 10.3390/ijms14024163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
207 Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12:2078-2086. [PMID: 18836784 DOI: 10.1007/s11605-008-0705-6] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
208 Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 2012;19:1663-9. [PMID: 22130621 DOI: 10.1245/s10434-011-2156-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
209 Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg 2021;108:403-11. [PMID: 33755097 DOI: 10.1093/bjs/znaa121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
210 Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS, Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BM. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol 2015;33:29-35. [PMID: 25403204 DOI: 10.1200/JCO.2014.57.5688] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
211 Hirata Y, Kobayashi T, Nishiumi S, Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Yamada T, Honda K, Azuma T, Yoshida M. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clinica Chimica Acta 2017;468:98-104. [DOI: 10.1016/j.cca.2017.02.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
212 Appel BL, Tolat P, Evans DB, Tsai S. Current Staging Systems for Pancreatic Cancer. The Cancer Journal 2012;18:539-49. [DOI: 10.1097/ppo.0b013e318278c5b5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
213 Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2013;71:1485-91. [PMID: 23532207 DOI: 10.1007/s00280-013-2147-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
214 Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S. EMT and tumor metastasis. Clin Transl Med. 2015;4:6. [PMID: 25852822 DOI: 10.1186/s40169-015-0048-3] [Cited by in Crossref: 381] [Cited by in F6Publishing: 392] [Article Influence: 54.4] [Reference Citation Analysis]
215 Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 2018;19:316-27. [PMID: 29303405 DOI: 10.1080/15384047.2017.1416937] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 11.3] [Reference Citation Analysis]
216 Su TS, Liang P, Lu HZ, Liang JN, Liu JM, Zhou Y, Gao YC, Tang MY. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. World J Gastroenterol 2015; 21(26): 8156-8162 [PMID: 26185389 DOI: 10.3748/wjg.v21.i26.8156] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
217 Al Haddad AH, Adrian TE. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opin Investig Drugs. 2014;23:1499-1515. [PMID: 25078674 DOI: 10.1517/13543784.2014.933206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
218 Minaga K, Takenaka M, Kamata K, Yoshikawa T, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakamoto H, Kitano M, Kudo M. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Cancers (Basel). 2018;10:50. [PMID: 29462851 DOI: 10.3390/cancers10020050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
219 Li Y, Tang CG, Zhao Y, Cao WY, Qu GF. Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria. World J Gastroenterol 2017; 23(15): 2757-2762 [PMID: 28487613 DOI: 10.3748/wjg.v23.i15.2757] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
220 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17(7): 867-897 [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 119] [Cited by in F6Publishing: 109] [Article Influence: 10.8] [Reference Citation Analysis]
221 Bevins J, Bhulani N, Goksu SY, Sanford NN, Gao A, Ahn C, Paulk ME, Terauchi S, Pruitt SL, Tavakkoli A, Rhodes RL, Kazmi SMA, Beg MS. Early Palliative Care Is Associated With Reduced Emergency Department Utilization in Pancreatic Cancer. Am J Clin Oncol 2021;44:181-6. [PMID: 33710133 DOI: 10.1097/COC.0000000000000802] [Reference Citation Analysis]
222 Moschovis D, Vasilaki E, Tzouvala M, Karamanolis G, Katifelis H, Legaki E, Vezakis A, Aravantinos G, Gazouli M. Association between genetic polymorphisms in long non-coding RNAs and pancreatic cancer risk. Cancer Biomark. 2019;24:117-123. [PMID: 30475759 DOI: 10.3233/cbm-181959] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
223 Stoof J, Harrold E, Mariottino S, Lowery MA, Walsh N. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front Cell Dev Biol 2021;9:749490. [PMID: 34712667 DOI: 10.3389/fcell.2021.749490] [Reference Citation Analysis]
224 Kuhn Y, Koscielny A, Glowka T, Hirner A, Kalff JC, Standop J. Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status. Eur J Surg Oncol. 2010;36:496-500. [PMID: 19748206 DOI: 10.1016/j.ejso.2009.08.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
225 Brauer BC. Intraductal Radiofrequency Ablation (RFA) for Pancreatic Cancer: Getting in Under the Wire? Dig Dis Sci 2015;60:3160-1. [PMID: 26209042 DOI: 10.1007/s10620-015-3811-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Malikowski T, Lehrke HD, Henry MR, Gleeson FC, Alberts SR, Kendrick ML, Lennon RJ, McWilliams RR, Takahashi N, Topazian MD, Gara N, Abu Dayyeh BK, Chandrasekhara V, Chari ST, Iyer PG, Rajan E, Storm AC, Wang KK, Levy MJ. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology 2020;20:110-5. [PMID: 31759906 DOI: 10.1016/j.pan.2019.11.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
227 Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010;252:499-505; discussion 505-6. [PMID: 20739850 DOI: 10.1097/sla.0b013e3181f1fd44] [Cited by in Crossref: 11] [Cited by in F6Publishing: 45] [Article Influence: 0.9] [Reference Citation Analysis]
228 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
229 Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs. 2009;20:477-482. [PMID: 19387337 DOI: 10.1097/cad.0b013e32832bd1e3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
230 Paparrizos J, White RW, Horvitz E. Screening for Pancreatic Adenocarcinoma Using Signals From Web Search Logs: Feasibility Study and Results. J Oncol Pract 2016;12:737-44. [PMID: 27271506 DOI: 10.1200/JOP.2015.010504] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
231 Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P. Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer. Radiother Oncol 2009;92:226-30. [PMID: 19435643 DOI: 10.1016/j.radonc.2009.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
232 Rankin AM, Sarkar S, Faller DV. Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol 2012;227:2586-94. [PMID: 21898405 DOI: 10.1002/jcp.22997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
233 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
234 Hollander LL, Guo X, Salem RR, Cha CH. The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. J Surg Res 2015;197:219-24. [PMID: 25982376 DOI: 10.1016/j.jss.2014.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
235 Youngwirth LM, Adam MA, Scheri RP, Roman SA, Sosa JA. Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer. Ann Surg Oncol 2016;23:403-9. [PMID: 26416710 DOI: 10.1245/s10434-015-4867-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
236 Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J Gastroenterol 2014; 20(32): 11182-11198 [PMID: 25170203 DOI: 10.3748/wjg.v20.i32.11182] [Cited by in CrossRef: 160] [Cited by in F6Publishing: 141] [Article Influence: 20.0] [Reference Citation Analysis]
237 Li Y, Wang Y, Li L, Kong R, Pan S, Ji L, Liu H, Chen H, Sun B. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Tumour Biol 2016;37:7345-55. [PMID: 26676634 DOI: 10.1007/s13277-015-4552-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
238 Lee JH, Giovannetti E, Hwang JH, Petrini I, Wang Q, Voortman J, Wang Y, Steinberg SM, Funel N, Meltzer PS, Wang Y, Giaccone G. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res 2012;18:524-33. [PMID: 22128300 DOI: 10.1158/1078-0432.CCR-11-1903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
239 Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132-8. [PMID: 25072261 DOI: 10.1038/bjc.2014.418] [Cited by in Crossref: 202] [Cited by in F6Publishing: 189] [Article Influence: 25.3] [Reference Citation Analysis]
240 Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res. 2012;173:105-112. [PMID: 22099597 DOI: 10.1016/j.jss.2011.09.020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.6] [Reference Citation Analysis]
241 Kim D, Zhu H, Nassri A, Mokdad A, Kukreja S, Polanco P, Huerta S, Ramzan Z. Survival analysis of veteran patients with pancreatic cancer. J Dig Dis. 2016;17:399-407. [PMID: 27235863 DOI: 10.1111/1751-2980.12361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
242 Nazari-vanani R, Azarpira N, Heli H. Development of self-nanoemulsifying drug delivery systems for oil extracts of Citrus aurantium L. blossoms and Rose damascena and evaluation of anticancer properties. Journal of Drug Delivery Science and Technology 2018;47:330-6. [DOI: 10.1016/j.jddst.2018.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
243 Newhook TE, Blais EM, Lindberg JM, Adair SJ, Xin W, Lee JK, Papin JA, Parsons JT, Bauer TW. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One 2014;9:e105631. [PMID: 25180633 DOI: 10.1371/journal.pone.0105631] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
244 Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart AC, Lecomte T, Aparicio T, Artru P, Thirot-Bidault A, Joubert F, Fanica D, Taieb J. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer. 2014;14:441. [PMID: 24929865 DOI: 10.1186/1471-2407-14-441] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
245 Öhlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013;13:154. [PMID: 23530721 DOI: 10.1186/1471-2407-13-154] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
246 Downs-Canner S, Zenati M, Boone BA, Varley PR, Steve J, Hogg ME, Zureikat A, Zeh HJ, Lee KK. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015;112:80-5. [PMID: 26153355 DOI: 10.1002/jso.23943] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
247 Carrato A, Cerezo L, Feliu J, Macarulla T, Martín-Pérez E, Vera R, Álvarez J, Botella-Carretero JI. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Clin Transl Oncol 2021. [PMID: 34363594 DOI: 10.1007/s12094-021-02674-x] [Reference Citation Analysis]
248 de Sousa Cavalcante L, Costa-Silva TA, Souza TA, Ienne S, Monteiro G. Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell-molecular insights about chemoresistance. Braz J Microbiol 2020;51:489-96. [PMID: 31515725 DOI: 10.1007/s42770-019-00154-7] [Reference Citation Analysis]
249 Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658-1663. [PMID: 19826418 DOI: 10.1038/sj.bjc.6605374] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 8.1] [Reference Citation Analysis]
250 Lin JC, Chan DC, Chen PJ, Chu HC, Chueh TH, Huang HH, Chang PY, Yu CP, Chang WK, Hsieh TY. Clinical characteristics of early onset pancreatic adenocarcinoma: a medical center experience and review of the literature. Pancreas 2011;40:638-9. [PMID: 21483255 DOI: 10.1097/MPA.0b013e318214fe56] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
251 Zhang Z, Pu J, Zhang H. Development and Validation of a Simple-to-Use Nomogram to Predict Early Death in Metastatic Pancreatic Adenocarcinoma. Front Oncol 2021;11:729175. [PMID: 34568061 DOI: 10.3389/fonc.2021.729175] [Reference Citation Analysis]
252 Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo H, Tian T, Ruan ZP, Wei YC, Jiang LL. Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study. Oncotarget. 2016;7:9586-9599. [PMID: 26840020 DOI: 10.18632/oncotarget.7078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
253 Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? J Gastrointest Oncol 2021;12:2450-60. [PMID: 34790406 DOI: 10.21037/jgo-2020-slapc-04] [Reference Citation Analysis]
254 LaRocca CJ, Han J, Gavrikova T, Armstrong L, Oliveira AR, Shanley R, Vickers SM, Yamamoto M, Davydova J. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 2015;157:888-98. [PMID: 25731784 DOI: 10.1016/j.surg.2015.01.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
255 Sun MR, Brennan DD, Kruskal JB, Kane RA. Intraoperative ultrasonography of the pancreas. Radiographics. 2010;30:1935-1953. [PMID: 21057128 DOI: 10.1148/rg.307105051] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
256 Chung KH, Ryu JK, Son JH, Lee JW, Jang DK, Lee SH, Kim YT. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Gut Liver. 2017;11:298-305. [PMID: 27965478 DOI: 10.5009/gnl16307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
257 Rosenthal MH, Lee A, Jajoo K. Imaging and Endoscopic Approaches to Pancreatic Cancer. Hematology/Oncology Clinics of North America 2015;29:675-99. [DOI: 10.1016/j.hoc.2015.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
258 Dobosz Ł, Kaczor M, Stefaniak TJ. Pain in pancreatic cancer: review of medical and surgical remedies: Pain in pancreatic cancer. ANZ J Surg 2016;86:756-61. [DOI: 10.1111/ans.13609] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
259 Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J Gastrointest Oncol 2016;7:239-47. [PMID: 27034792 DOI: 10.3978/j.issn.2078-6891.2015.109] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
260 Gleason MX, Mdzinarishvili T, Are C, Sasson A, Sherman A, Shats O, Sherman S. Prognostic estimator of survival for patients with localized and extended pancreatic ductal adenocarcinoma. Cancer Inform 2013;12:103-14. [PMID: 23589669 DOI: 10.4137/CIN.S11496] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
261 Tosolini C, Michalski CW, Kleeff J. Response evaluation following neoadjuvant treatment of pancreatic cancer patients. World J Gastrointest Surg 2013; 5(2): 12-15 [PMID: 23515366 DOI: 10.4240/wjgs.v5.i2.12] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
262 Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595-600. [PMID: 22006521 DOI: 10.1002/jso.22118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
263 Vashist YK, Uzungolu G, Kutup A, Gebauer F, Koenig A, Deutsch L, Zehler O, Busch P, Kalinin V, Izbicki JR, Yekebas EF. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. J Surg Oncol 2011;104:305-11. [PMID: 21495030 DOI: 10.1002/jso.21926] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
264 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
265 Khalafalla FG, Khan MW. Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth Metastasis. 2017;10:1179064417709287. [PMID: 28579826 DOI: 10.1177/1179064417709287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
266 Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept. Int J Surg 2015;21 Suppl 1:S15-21. [PMID: 26123383 DOI: 10.1016/j.ijsu.2015.04.093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
267 Yoon WJ, Seo DW. [Endoscopic Ultrasound-guided Local Therapy of Pancreatic Tumors]. Korean J Gastroenterol 2015;66:154-8. [PMID: 26387698 DOI: 10.4166/kjg.2015.66.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Aktekin A, Torun M, Ustaalioğlu BBO, Ozkara S, Cakır O, Muftuoglu T. The effects of systemic inflammatory response on prognosis of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:155-62. [PMID: 31225417 DOI: 10.14701/ahbps.2019.23.2.155] [Reference Citation Analysis]
269 Pérez-Aguado G, de la Mata DMA, Valenciano CML, Sainz IFU. Endoscopic ultrasonography-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer: An update. World J Gastrointest Endosc 2021; 13(10): 460-472 [PMID: 34733407 DOI: 10.4253/wjge.v13.i10.460] [Reference Citation Analysis]
270 Luu AM, Künzli B, Hoehn P, Munding J, Lukas C, Uhl W, Braumann C. Prognostic value and impact of cerebral metastases in pancreatic cancer. Acta Chir Belg 2020;120:30-4. [PMID: 30614389 DOI: 10.1080/00015458.2018.1549379] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
271 Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y, Lv J, Song Z, Li Y, Ji L, Pan S, Jiang H, Sun B. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Biochem Pharmacol 2014;88:322-33. [PMID: 24522113 DOI: 10.1016/j.bcp.2014.01.041] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
272 Osteikoetxea X, Benke M, Rodriguez M, Pálóczi K, Sódar BW, Szvicsek Z, Szabó-Taylor K, Vukman KV, Kittel Á, Wiener Z, Vékey K, Harsányi L, Szűcs Á, Turiák L, Buzás EI. Detection and proteomic characterization of extracellular vesicles in human pancreatic juice. Biochem Biophys Res Commun 2018;499:37-43. [PMID: 29550476 DOI: 10.1016/j.bbrc.2018.03.107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
273 Desai V, Patel K, Sheth R, Barlass U, Chan YM, Sclamberg J, Bishehsari F. Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma. Visc Med 2020;36:220-6. [PMID: 32775353 DOI: 10.1159/000507457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
274 Welinsky S, Lucas AL. Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver 2017;11:761-70. [PMID: 28609837 DOI: 10.5009/gnl16414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
275 Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175-2181. [PMID: 19491823 DOI: 10.1038/ajg.2009.276] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 12.7] [Reference Citation Analysis]
276 Ocuin LM, Miller-Ocuin JL, Novak SM, Bartlett DL, Marsh JW, Tsung A, Lee KK, Hogg ME, Zeh HJ, Zureikat AH. Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. HPB (Oxford) 2016;18:835-42. [PMID: 27506992 DOI: 10.1016/j.hpb.2016.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
277 Woei-A-Jin FJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer 2016;115:332-8. [PMID: 27404454 DOI: 10.1038/bjc.2016.170] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
278 Wong JC, Raman S. Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging. 2010;35:471-480. [PMID: 19468791 DOI: 10.1007/s00261-009-9539-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
279 Mirkin KA, Hollenbeak CS, Wong J. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. J Gastrointest Oncol 2017;8:778-88. [PMID: 29184681 DOI: 10.21037/jgo.2017.07.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
280 Ryska M, Rudis J. Pancreatic fistula and postoperative pancreatitis after pancreatoduodenectomy for pancreatic cancer. Hepatobiliary Surg Nutr 2014;3:268-75. [PMID: 25392838 DOI: 10.3978/j.issn.2304-3881.2014.09.05] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
281 Hamada T, Nakai Y, Isayama H, Yasunaga H, Matsui H, Takahara N, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer 2016;65:11-20. [DOI: 10.1016/j.ejca.2016.05.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
282 Yamamoto M, Imagawa DK, Katz MH. Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Rev Anticancer Ther. 2008;8:1611-1621. [PMID: 18925853 DOI: 10.1586/14737140.8.10.1611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
283 Ungaro A, Orsi F, Casadio C, Galdy S, Spada F, Cella CA, Tonno CD, Bonomo G, Vigna PD, Murgioni S, Frezza AM, Fazio N. Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. Ecancermedicalscience. 2016;10:635. [PMID: 27170835 DOI: 10.3332/ecancer.2016.635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
284 Ruarus A, Vroomen L, Puijk R, Scheffer H, Zonderhuis B, Kazemier G, van den Tol M, Berger F, Meijerink M. Irreversible Electroporation in Hepatopancreaticobiliary Tumours. Can Assoc Radiol J 2018;69:38-50. [DOI: 10.1016/j.carj.2017.10.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
285 Klompmaker S, van Hilst J, Gerritsen SL, Adham M, Teresa Albiol Quer M, Bassi C, Berrevoet F, Boggi U, Busch OR, Cesaretti M, Dalla Valle R, Darnis B, De Pastena M, Del Chiaro M, Grützmann R, Diener MK, Dumitrascu T, Friess H, Ivanecz A, Karayiannakis A, Fusai GK, Labori KJ, Lombardo C, López-Ben S, Mabrut JY, Niesen W, Pardo F, Perinel J, Popescu I, Roeyen G, Sauvanet A, Prasad R, Sturesson C, Lesurtel M, Kleeff J, Salvia R, Besselink MG; E-AHPBA DP-CAR study group. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Ann Surg Oncol 2018;25:1440-7. [PMID: 29532342 DOI: 10.1245/s10434-018-6391-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
286 Buanes TA. Pancreatic cancer-improved care achievable. World J Gastroenterol 2014; 20(30): 10405-10418 [PMID: 25132756 DOI: 10.3748/wjg.v20.i30.10405] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
287 Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J. Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome. Annals of Surgery 2011;254:311-9. [DOI: 10.1097/sla.0b013e31821fd334] [Cited by in Crossref: 280] [Cited by in F6Publishing: 116] [Article Influence: 25.5] [Reference Citation Analysis]
288 Dong D, Zhao M, Zhang J, Huang M, Wang Y, Qi L, Wan CF, Yu X, Song T. Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial. Anesthesiology 2021;135:686-98. [PMID: 34398950 DOI: 10.1097/ALN.0000000000003936] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Samawi HH, Yin Y, Lim HJ, Cheung WY. Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. J Gastrointest Canc 2018;49:429-36. [DOI: 10.1007/s12029-017-9988-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
290 Cucchetti A, Ercolani G, Taffurelli G, Serenari M, Maroni L, Pezzilli R, Del Gaudio M, Ravaioli M, Cescon M, Pinna AD. A comprehensive analysis on expected years of life lost due to pancreatic cancer. Pancreatology 2016;16:449-53. [PMID: 26951889 DOI: 10.1016/j.pan.2016.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
291 Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011;17:5812-5821. [PMID: 21652542 DOI: 10.1158/1078-0432.ccr-11-0695] [Cited by in Crossref: 111] [Cited by in F6Publishing: 68] [Article Influence: 10.1] [Reference Citation Analysis]
292 Topkan E, Parlak C, Yapar F. Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy. Pancreatology 2012;12:434-9. [DOI: 10.1016/j.pan.2012.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
293 Yuan Y, Shen H, Hu XY, Gu FY, Li MD, Zhong X. Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Med Oncol 2012;29:957-61. [PMID: 21387165 DOI: 10.1007/s12032-011-9892-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
294 Kamarajah SK, Al-Rawashdeh W, White SA, Abu Hilal M, Salti GI, Dahdaleh FS. Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer A population-based cohort study. Eur J Surg Oncol 2021:S0748-7983(21)00724-1. [PMID: 34518052 DOI: 10.1016/j.ejso.2021.09.002] [Reference Citation Analysis]
295 Wu G, Maharjan S, Kim D, Kim JN, Park BK, Koh H, Moon K, Lee Y, Kwon HJ. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model. Int J Mol Sci 2018;19:E2004. [PMID: 29987260 DOI: 10.3390/ijms19072004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
296 Schmitz-Winnenthal FH, Schmidt T, Lehmann M, Beckhove P, Kieser M, Ho AD, Dreger P, Büchler MW. Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study. BMC Cancer 2014;14:168. [PMID: 24612467 DOI: 10.1186/1471-2407-14-168] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20 Suppl 3:S415-S423. [PMID: 23096698 DOI: 10.1245/s10434-012-2686-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
298 Rosati A, Bersani S, Tavano F, Dalla Pozza E, De Marco M, Palmieri M, De Laurenzi V, Franco R, Scognamiglio G, Palaia R, Fontana A, di Sebastiano P, Donadelli M, Dando I, Medema JP, Dijk F, Welling L, di Mola FF, Pezzilli R, Turco MC, Scarpa A. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Am J Pathol 2012;181:1524-9. [PMID: 22944597 DOI: 10.1016/j.ajpath.2012.07.016] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
299 Petermann D, Demartines N, Schäfer M. Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head? HPB (Oxford). 2013;15:872-881. [PMID: 23458601 DOI: 10.1111/hpb.12052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
300 Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy 2018;18:51-62. [DOI: 10.1080/14737140.2018.1403319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]